PURPOSE: Carboplatin-induced ototoxicity remains poorly defined but is of potential great consequence in children with retinoblastoma. We retrospectively assessed the incidence of ototoxicity and its risk factors in children with retinoblastoma who were treated with carboplatin. PATIENTS AND METHODS: We reviewed the audiologic test results of 60 patients with retinoblastoma who received front-line treatment with systemic carboplatin and vincristine according to the St Jude RET-3 protocol (n = 23) or best clinical management (n = 37). Ototoxicity was evaluated by three different grading systems. RESULTS: Twelve patients (20%) developed ototoxicity at some time after treatment initiation; however, ototoxicity resolved in two patients, and thus,10 patients (17%) had sustained hearing loss as documented at their most recent audiologic evaluation. Nine of these 10 patients had grade 3 or 4 ototoxicity, and nine patients were less than 6 months of age at the start of chemotherapy. Age at the start of chemotherapy was the only risk factor identified as a significant predictor of sustained hearing loss. Younger age was associated with an increased incidence of hearing loss. The different ototoxicity grading systems showed good overall agreement in the identification of patients with ototoxicity. Agreement was greatest between the Brock and Children's Cancer Group systems. CONCLUSION: We found that young patients with retinoblastoma who were treated with systemic carboplatin had a higher incidence of ototoxicity than previously reported. Younger patients (< 6 months of age at the start of treatment) were more likely to have ototoxicity than were older patients. Children treated with carboplatin should routinely undergo thorough, long-term audiologic monitoring.
PURPOSE:Carboplatin-induced ototoxicity remains poorly defined but is of potential great consequence in children with retinoblastoma. We retrospectively assessed the incidence of ototoxicity and its risk factors in children with retinoblastoma who were treated with carboplatin. PATIENTS AND METHODS: We reviewed the audiologic test results of 60 patients with retinoblastoma who received front-line treatment with systemic carboplatin and vincristine according to the St Jude RET-3 protocol (n = 23) or best clinical management (n = 37). Ototoxicity was evaluated by three different grading systems. RESULTS: Twelve patients (20%) developed ototoxicity at some time after treatment initiation; however, ototoxicity resolved in two patients, and thus,10 patients (17%) had sustained hearing loss as documented at their most recent audiologic evaluation. Nine of these 10 patients had grade 3 or 4 ototoxicity, and nine patients were less than 6 months of age at the start of chemotherapy. Age at the start of chemotherapy was the only risk factor identified as a significant predictor of sustained hearing loss. Younger age was associated with an increased incidence of hearing loss. The different ototoxicity grading systems showed good overall agreement in the identification of patients with ototoxicity. Agreement was greatest between the Brock and Children's Cancer Group systems. CONCLUSION: We found that young patients with retinoblastoma who were treated with systemic carboplatin had a higher incidence of ototoxicity than previously reported. Younger patients (< 6 months of age at the start of treatment) were more likely to have ototoxicity than were older patients. Children treated with carboplatin should routinely undergo thorough, long-term audiologic monitoring.
Authors: Cas Smits; Suzanne J Swen; S Theo Goverts; Annette C Moll; Saskia M Imhof; Antoinette Y N Schouten-van Meeteren Journal: Eur J Cancer Date: 2006-01-11 Impact factor: 9.162
Authors: Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo Journal: Nat Rev Clin Oncol Date: 2011-06-28 Impact factor: 66.675
Authors: Suzanne K Pierson; Susan E Caudle; Kevin R Krull; Jody Haymond; Ross Tonini; John S Oghalai Journal: Laryngoscope Date: 2007-09 Impact factor: 3.325
Authors: Heng Xu; Giles W Robinson; Jie Huang; Joshua Yew-Suang Lim; Hui Zhang; Johnnie K Bass; Alberto Broniscer; Murali Chintagumpala; Ute Bartels; Sri Gururangan; Tim Hassall; Michael Fisher; Richard Cohn; Tetsuji Yamashita; Tal Teitz; Jian Zuo; Arzu Onar-Thomas; Amar Gajjar; Clinton F Stewart; Jun J Yang Journal: Nat Genet Date: 2015-02-09 Impact factor: 38.330
Authors: Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Jessica Sparrow; Rachel Brennan; Shenghua Mao; Kirsten K Ness; Carlos Rodriguez-Galindo; Matthew Wilson; Ibrahim Qaddoumi Journal: J Pediatr Rehabil Med Date: 2016-05-31
Authors: Johnnie K Bass; Wei Liu; Pia Banerjee; Tara M Brinkman; Daniel A Mulrooney; Amar Gajjar; Alberto S Pappo; Thomas E Merchant; Gregory T Armstrong; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: JAMA Oncol Date: 2020-09-01 Impact factor: 31.777
Authors: Dawn Konrad-Martin; Kristin Knight; Garnett P McMillan; Laura E Dreisbach; Elsa Nelson; Marilyn Dille Journal: Ear Hear Date: 2020 Mar/Apr Impact factor: 3.570
Authors: Qiuling Liu; Yafeng Wang; Han Wang; Yingying Liu; Tao Liu; Patricia Elena Kunda Journal: J Cancer Res Clin Oncol Date: 2013-05-21 Impact factor: 4.553
Authors: Joann L Ater; Caihong Xia; Claire M Mazewski; Timothy N Booth; David R Freyer; Roger J Packer; Richard Sposto; Gilbert Vezina; Ian F Pollack Journal: Cancer Date: 2016-04-08 Impact factor: 6.860